WASHINGTON (Reuters) - The most commonly used tool for detecting prostate cancer, routine PSA screening, has become "a hugely expensive public health disaster," its discoverer said on Wednesday. Dr. Richard Ablin of the University of Arizona joined the ongoing debate over the blood test, saying the screening procedure is too costly and ineffective. "I never dreamed that my discovery four decades ...

NEW YORK (Reuters Health) - New research suggests that the type of specialist a prostate cancer patient sees -- rather than the patient's own preference -- may determine the treatment he receives. This is problematic, the study's authors say, because none of the options now available for treating localized prostate cancer have been shown to be any better than the others ...

Months after experts discounted the importance of routine mammograms and Pap smears for many women, the American Cancer Society is warning more explicitly than ever that regular testing for prostate cancer is of questionable value too, and can do men more harm than good. The cancer ...

For the first time, an experimental drug has extended the lives of men with advanced prostate cancer who are no longer responding to other treatments and are out of options for fighting the disease, a company-led study found. The benefit was modest — an extra 10 weeks — but ...